Insider trade

Director received an award of 323 BSX derivative securities

Traded Mar 2, 2026 · Filed Mar 5, 2026

Boston ScientificBSX

323
Derivative units

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Mar 2, 2026
Reporting period: Not applicable
Filed with the SEC: Mar 5, 2026

DirectorGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001225208-26-003177
Filed / recorded

Mar 5, 2026, 12:35 AM UTC

Added to OQRO

Oct 2, 2026, 12:27 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

BOSTON SCIENTIFIC CORP

Issuer CIK

885725

Ticker

BSX

Reporting person

Cathy R Smith

Relationship

Director

Security

Deferred Stock Units

Table

Derivative (Table II)

Transaction date

Mar 2, 2026

Transaction code

A

Shares / units

323

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

879

Ownership form

Direct

Amendment

No

Footnotes from the filing

Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
Grant of deferred stock units in lieu of 100% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $24,662.50 (representing 100% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.